Charles Rowland - Blueprint Medicines Independent Director
| BPMC Stock | USD 92.26 0.03 0.03% |
Director
Mr. Charles A. Rowland, Jr., serves as an Independent Director of the Company. He has served as a member of our board of directors since March 2015. From April 2016 to February 2017, Mr. Rowland served as president and chief executive officer of Aurinia Pharmaceuticals Inc., or Aurinia, and as a member of the board of directors of Aurinia from July 2014 to February 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated, or ViroPharma, an international biopharmaceutical company, from October 2008 until it was acquired by Shire plc in January 2014. Prior to joining ViroPharma, from 2006 to 2008, Mr. Rowland served as executive vice president and chief financial officer, as well as the interim cochief executive officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management. Mr. Rowland previously held positions of increasing responsibility at the following biopharmaceutical companies Biovail Pharmaceuticals, Inc., Breakaway Technologies, Inc., Pharmacia Corporationrationration, Novartis AG and BristolMyers Squibb Co. Mr. Rowland has served as a member of the board of directors and chairman of the audit committee and compensation committee of Orchard Therapeutics plc since June 2018, as a member of the board of directors, chairman of the compensation committee and member of the audit committee of Viking Therapeutics, Inc. since July 2017 and as a member of the board of directors and chairman of the audit committee and compensation committee of Nabriva Therapeutics, AG, a biotechnology company based in Dublin, Ireland, since January 2015. In addition, Mr. Rowland currently serves on the board of directors and as chairman of the audit committee of Generation Bio, a privately held biopharmaceutical company. Mr. Rowland served as a member of the board of directors and audit committee of Idenix Pharmaceuticals, Inc since 2015.
| Age | 59 |
| Tenure | 9 years |
| Address | 45 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 374 7580 |
| Web | https://www.blueprintmedicines.com |
Charles Rowland Latest Insider Activity
Tracking and analyzing the buying and selling activities of Charles Rowland against Blueprint Medicines stock is an integral part of due diligence when investing in Blueprint Medicines. Charles Rowland insider activity provides valuable insight into whether Blueprint Medicines is net buyers or sellers over its current business cycle. Note, Blueprint Medicines insiders must abide by specific rules, including filing SEC forms every time they buy or sell Blueprint Medicines'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Charles Rowland over six months ago Exercise or conversion by Charles Rowland of 40000 shares of Viking Therapeutics subject to Rule 16b-3 |
Blueprint Medicines Management Efficiency
The company has return on total asset (ROA) of (0.2534) % which means that it has lost $0.2534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5714) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Alan Howarth | Terns Pharmaceuticals | 69 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 |
Blueprint Medicines Corp Leadership Team
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Lydon, Director | ||
| Michael Landsittel, Interim Principal Accounting and Financial Officer and Sr. Director of Fin. | ||
| George Demetri, Independent Director | ||
| Dr MBA, Chief Officer | ||
| Anthony Boral, Senior Vice President - Clinical Development | ||
| Tracey Esq, Chief VP | ||
| Kathryn Haviland, Chief Business Officer | ||
| Jeffrey Albers, President CEO, Director | ||
| Alexis Borisy, Director | ||
| Stephen Knight, Director | ||
| Christopher Murray, Senior Vice President Technical Operations | ||
| Tracey McCain, Executive Vice President Chief Legal Officer, Secretary | ||
| Alexis AM, CoFounder Director | ||
| Daniel Lynch, Chairman of the Board | ||
| Marion Dorsch, Chief Scientific Officer | ||
| Mark Goldberg, Director | ||
| Fouad MD, President Development | ||
| Kristin Hodous, IR Contact Officer | ||
| Charles Rowland, Independent Director | ||
| Ariel Hurley, Principal Accounting Officer | ||
| Christina Rossi, Chief Commercial Officer | ||
| Lonnel Coats, Independent Director | ||
| JD MBA, Ex Chairman | ||
| Jenna Cohen, Director Relations | ||
| Christoph Lengauer, Chief Scientific Officer | ||
| Thilo Schroeder, Director | ||
| Lynn Seely, Director |
Blueprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Blueprint Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (2.03) % | ||||
| Operating Margin | (1.46) % | ||||
| Current Valuation | 5.71 B | ||||
| Shares Outstanding | 61.23 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 4.37 M | ||||
| Price To Earning | 7.93 X |
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving together with Blueprint Stock
| 0.78 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.66 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
Moving against Blueprint Stock
| 0.43 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.